Eywa Pharma Private Limited

Based in Singapore, Eywa Pharma Private Limited develops and distributes affordable generic pharmaceuticals, focusing on enhancing patient access to essential medications across various healthcare markets. Eywa Pharma Private Limited was founded in 2015 in Singapore. The company specializes in the development of generic pharmaceuticals. It has raised USD 38.

00 mn in its latest funding round, Series B, from investors including Eight Roads Ventures, Natco Pharma Limited, and Iwell Investments, totaling USD 38. 00 mn raised to date. Eywa Pharma has been involved in 3 deals, the most recent being on April 11, 2023. The current company valuation stands at USD 103.

49 mn. Eywa Pharma specializes in the development and distribution of affordable, high-quality generic pharmaceuticals, addressing healthcare challenges for an aging global population. The company offers a diverse portfolio of medications across various therapeutic areas, primarily targeting healthcare providers, pharmacies, and hospitals in emerging markets in Asia, Africa, and Latin America, ensuring essential medicines are accessible to patients. Eywa Pharma generated revenue of USD 21,095,137 in 2020, with an EBITDA of USD -9,849,678 for the same year.

The company's revenue is driven by sales of its generic pharmaceutical products, utilizing a distribution model that includes partnerships with wholesalers and direct transactions with healthcare providers, positioning itself for sustainable revenue growth. In August 2023, Eywa Pharma Private Limited raised USD 38 mn in Series B funding aimed to support the launch of new products designed to address patient needs. The company plans to expand into additional emerging markets across Asia and Africa by the end of 2024. Recent funding will facilitate these expansions and the development of innovative healthcare solutions.